Natus Medical announced Wednesday after the close that CEO Jim Hawkins is retiring and will be immediately replaced by CFO Jonathan Kennedy, and that Natus Q2 revenue guidance range was tightened to $130M-$131M from $129M-131M. Roth Capital analyst Scott Henry said the announcement was "not a surprise," added that the internal choice signals the "business is stable," and concluded that he was encouraged that the transition was not used to lower guidance. Henry maintained a Buy rating and $39 price target on Natus Medical shares, calling it a "good value and turnaround story."